http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Jee-woo Kim ),( Yeo-seon Kwon ),( Yoon-young Chang ),( Sung-ho Hong ),( Jung-won Shin ),( Jung-im Na ),( Chang-hun Huh ) 대한피부과학회 2020 대한피부과학회 학술발표대회집 Vol.72 No.1
Background: Low-level laser therapy (LLLT) has been reported to promote hair growth in androgenic alopecia (AGA). Objectives: The aim of this study is to investigate clinical efficacy and safety of a brand-new home-use LLLT device with a newly designed array of light source and software optimized for individual types of AGA. Methods: The study was designed and conducted as a randomized, double-blind, sham device-controlled trial. 48 subjects (39 men and 9 women) were participated and randomly assigned in a 2:1 ratio to use either test device (LG Pra’L HGN1, LG electronics, Korea) or sham device. The subjects used LLLT device 3 times a week for a total of 16 weeks. Phototrichogram was used to measure hair density and hair thickness at 0, 8, and 16-week. Adverse events were closely monitored. Results: After 16 weeks using the device, the test group showed significant increase in hair terms of hair density and hair thickness compared to control. In the test group, the hair density increased 9.94% at 8-week and 18.34% at 16-week from baseline. The hair thickness increased 10.08% at 8-week and 16.29% at 16-week from baseline, too. Conclusion: The home-use LLLT device with novel array of light source and individualized program according to the types of hair loss appears to be an effective and safe treatment modality for both male and female AGA patients.
Jee-Woo Kim,Yeo-Seon Kwon,Yoon-Young Chang,Sung-Ho Hong,Jung-Won Shin,Jung-Im Na,허창훈 대한의학레이저학회 2020 MEDICAL LASERS Vol.9 No.2
Background and Objectives Low-level laser therapy (LLLT) is used widely to promote hair growth in androgenetic alopecia (AGA). This study examined the clinical efficacy and safety of a home-use LLLT device with a newly designed array of light sources and software optimized for individual types of AGA. Materials and Methods The study was a randomized, double-blind, sham device-controlled trial. Forty-eight subjects (39 men and nine women) were assigned randomly in a 2:1 ratio to use either the test device (LG Pra’L HGN1, LG electronics, Korea) or sham device. The subjects used the LLLT device three times a week for 16 weeks. Phototrichogram was used to measure the hair density and hair thickness at 0, 8, and 16-weeks. Adverse events were closely monitored. Results After 16 weeks of using the device, the test group showed a significant increase in hair density and hair thickness compared to the control. In the test group, the hair density increased 6.96 counts/cm2 at eight weeks and 13.67 counts/cm2 at 16 weeks from the baseline. The hair thickness increased 7.21 μm at eight weeks and 11.80 μm at 16 weeks compared to the baseline. Conclusion The home-use LLLT device with a novel array of light sources and an individualized program according to the types of hair loss appears to be an effective and safe treatment modality for both male and female AGA patients.
Yoon, Hye Eun,Hyoung, Bok Jin,Hwang, Hyeon Seok,Lee, So Young,Jeon, Youn Joo,Song, Joon Chang,Oh, Eun-Jee,Park, Sun Cheol,Choi, Bum Soon,Moon, In Sung,Kim, Yong Soo,Yang, Chul Woo The Korean Academy of Medical Sciences 2009 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.24 No.suppl
<P>Intravenous immunoglobulin (IVIG) and/or plasmapheresis (PP) are effective in preventing antibody-mediated rejection (AMR) of kidney allografts, but AMR is still a problem. This study reports our experience in living donor renal transplantation in highly sensitized patients. Ten patients with positive crossmatch tests or high levels of panel-reactive antibody (PRA) were included. Eight patients were desensitized with pretransplant PP and low dose IVIG, and two were additionally treated with rituximab. Allograft function, number of acute rejection (AR) episodes, protocol biopsy findings, and the presence of donor-specific antibody (DSA) were evaluated. With PP/IVIG, six out of eight patients showed good graft function without AR episodes. Protocol biopsies revealed no evidence of tissue injury or C4d deposits. Of two patients with AR, one was successfully treated with PP/IVIG, but the other lost graft function due to de novo production of DSA. Thereafter, rituximab was added to PP/IVIG in two cases. Rituximab gradually decreased PRA levels and the percentage of peripheral CD20+ cells. DSA was undetectable and protocol biopsy showed no C4d deposits. The graft function was stable and there were no AR episodes. Conclusively, desensitization using PP/IVIG with or without rituximab increases the likelihood of successful living donor renal transplantation in sensitized recipients.</P>
( Sang Woong Youn ),( Tae Yoon Kim ),( Byung Soo Kim ),( Seung Chul Lee ),( Jeung Hoon Lee ),( Yong-beom Choe ),( Joo-heung Lee ),( Jee-ho Choi ),( Joo Young Roh ),( Seong Jin Jo ),( Eun-so Lee ),( Mi 대한피부과학회 2018 대한피부과학회 학술발표대회집 Vol.70 No.2
Background: The Phase Ⅲ studies, VOYAGE 1 and 2, were conducted to assess guselkumab for the treatment of patients with moderate to severe psoriasis. However, these studies included a worldwide study population. Objectives: To determine the efficacy and safety of guselkumab in Korean patients. Methods: This analysis included 28 patients from VOYAGE 1 and 98 patients from VOYAGE 2. In total, 126 patients were analyzed. Outcomes through week 28 were analyzed due to differences in design after week28. Results: Of 126 Korean patients randomized, 30 received placebo, 63 were assigned to guselkumab, and 33 received adalimumab. Guselkumab was superior to adalimumab in achieving an IGA 0 score (clear skin) at week 12 (31.7% vs 0.0%, p<0.001) and at week 24 (52.4% vs 21.2%, p=0.004), respectively. Among patients treated with guselkumab, 40 of 63 (63.5%) achieved a PASI75 response at week 8; at week 24, a significantly higher proportion of guselkumab patients achieved a PASI 75 compared to adalimumab patients (93.7% vs 66.7%, respectively, p<0.001). In addition, higher proportions of guselkumab patients achieved PASI 90 and PASI 100 than adalimumab patients at week 24 (PASI90; 73.0% vs 57.6%, p=0.168 / PASI100; 20.6% vs 15.2%, p=0.591, respectively). Through week 28, guselkumab and adalimumab showed comparable safety profiles. Conclusion: The efficacy and safety of guselkumab in Korean psoriasis patients through 28 weeks was consistent with findings reported for the VOYAGE1 and 2 trials.
Effects of Early Operation in Patients Who Diagnosed Complicated Parapneumonic Effusion
( Sung Jun Chung ),( Hyo Jun Jang ),( Jee Yea Choi ),( Joonkyung Kim ),( Jun Ho Lee ),( Hyun Lee ),( Dong Won Park ),( Sang-heon Kim ),( Jang Won Sohn ),( Hyuck Kim ),( Ho Joo Yoon ),( Won Sang Chung 대한결핵 및 호흡기학회 2020 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.128 No.-
Purpose Thoracic empyema is defined as active suppuration within the pleural space and its treatment is controversial. Recently treatment of empyema is changing observation of empyema formation to early invasive treatment with the operation. This study compared the outcomes of early surgery and delayed surgery Method We retrospectively reviewed 40 patients who underwent surgery for complicated parapneumonic effusion from January of 2013 to May of 2020. The early group was defined as operation with empyema diagnosed within 1 week. Results Among 40 patients, 22 patients received early surgery, and 18 patients received delayed surgery. Stage III empyema was prevalent in the delayed group (27.3% vs 76.9%, p=0.004). Operative time was longer in the delayed group (87.5 vs 132.5 min, p=0.004). Intraoperative blood loss was more in the delayed group (200ml vs 750ml, p=0.009). The hospital stay was longer in the delayed group (18.5 days vs 30.0 days, p<0.001). The complication rate was not different between groups (31.8% vs 33.3%, p=0.919). The mortality rate was no significance between the two groups (4.5% vs 5.6%, p=0.884). Conclusion Delayed surgical treatment make operation difficult. Although inactive infected phase, early surgical treatment did not increase postoperative morbidity and mortality.
( Sang Gook Seo ),( Se Hwan Park ),( Jin-hwan Yoon ),( Byeong-wan Kim ),( Hyunseok Jee ) 한국운동생리학회(구 한국운동과학회) 2020 운동과학 Vol.29 No.2
PURPOSE: The purpose of this study was to investigate the effects of 5 weeks of basic military training on the physical fitness and blood biochemical factors in obese military recruits. METHODS: Forty-eight male recruits (20-25 years of age) were randomly assigned to the Control group and Exercise group. Both groups completed 5 weeks of basic military training. The Exercise group additionally performed a resistance exercise twice daily in the morning and afternoon (1-3 sets, 3 days per week) and power walking (60-80% HRmax, 30 minutes) four times weekly. Four body composition variables, physical fitness factors, serum lipid profiles, and obesity-related hormone levels were analyzed. RESULTS: Body weight, body fat ratio, body mass index, and waist circumference were significantly decreased in both groups between pre- and post-exercise tests (p<.01). However, no changes in these parameters were observed between the Control and Exercise groups. Twenty-meter shuttle running and maximal oxygen uptake were significantly increased post exercise (p<.001). Total cholesterol, triglyceride, and low-density lipoprotein levels were significantly decreased in both (Control and Exercise) post-exercise tests (p<.05). Leptin in both groups was significantly decreased; however, ghrelin showed a reverse pattern (p<.01). A significantly changed maximal oxygen uptake value via training was noted in both groups (p<.001). The time and interaction between the groups and the time were also significantly affected (p<.001). CONCLUSIONS: Our findings suggest that an additional exercise-training program with the basic military training plays an important role in improving military fitness and combat power.
Decreased Insulin Secretion in Women with Previous Gestational
Yoon Pyo Lee,Soo Kyung Lim,Ji young Chang,Eun kyo Jung,Youn-i Choi,Jee-Young Oh,Youngsun Hong,Yeon-Ah Sung,Hyejin Lee 이화여자대학교 의과학연구소 2015 EMJ (Ewha medical journal) Vol.38 No.1
Objectives: Gestational diabetes mellitus (GDM) affects 2%–4% of the all pregnant women, and it is a major risk factor for development of type 2 DM. We performed this cross-sectional study to determine whether there were defects in insulin secretory capacity or insulin sensitivity in women with previous GDM. Methods: On 6–8 weeks after delivery, 75 g oral glucose tolerance test was performed in 36 women with previous GDM and 19 non-pregnant control women matched with age and weight. Intravenous glucose tolerance test was performed on 10–14 weeks after delivery. Insulin secretory capacity measured as the acute insulin response to glucose (AIRg) and insulin sensitivity as minimal model derived sensitivity index (SI) were obtained. AIRg×SI (β-cell disposition index) was used as an index of β-cell function. Results: Women with previous GDM were classified into normal glucose tolerance (postpartum-NGT, n=19) and impaired glucose tolerance (postpartum-IGT, n=17). Postpartum fasting glucose levels were significantly higher in postpartum-IGT compared to postpartum-NGT and control (P<0.05). AIRg×SI was significantly lower in postpartum-IGT compared to control (P<0.05). SI was lower in postpartum-NGT and postpartum-IGT compared to control, but the difference did not have the statistical significance. Frequency of parental history of type 2 diabetes was significantly greater in postpartum-IGT compared to postpartum-NGT (P<0.05). Conclusion: Women with previous GDM showed impaired insulin secretion although their glucose tolerance states were restored to normal. It suggests impaired early insulin secretion may be a major pathophysiologic factor for development of type 2 DM, and this defect may be genetically determined.